MedTrace Logo

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

NCT03089645 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-07-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

MEDI5083 monotherapy

Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab

BIOLOGICAL

MEID5083 with Durvalumab or Tremelimumab

Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab

BIOLOGICAL

Medi5083 with Durvalumab and Docetaxel

Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • MedImmune LLC · Sponsor GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
101 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-21
Primary Completion
2020-06-23
Completion
2020-06-23
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089645 on ClinicalTrials.gov